DLA Piper advises Pfizer Ventures and Earlybird Venture Capital on Grey Wolf financing

DLA Piper has advised premier Life Science industry investors, Pfizer Ventures and Earlybird Venture Capital on their investment in Grey Wolf Therapeutics (Grey Wolf).

Grey Wolf is a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation. On the 26 January it closed on its oversubscribed $49 million Series B financing which was co-led by Pfizer Ventures and Earlybird Venture Capital. The premier syndicate also included investment from new investors Oxford Science Enterprises and British Patient Capital and existing investors Canaan and Andera Partners.

Proceeds of the fundraising will support the continued development of Grey Wolf’s first-of-its-kind immuno-oncology approaches designed to overcome key resistance mechanisms through the creation of novel cancer antigens. This includes the anticipated advancement of the company’s lead asset, GRWD5769, into a Phase 1/2 clinical trial in the first half of 2023.

The London based Emerging Growth and Venture Capital team at DLA Piper was led by Corporate partner Jon Kenworthy and Senior Associate Dylan Kennett. They were supported by Corporate Associates Tom Watkins and Annisa Chan. Intellectual Property and Life Sciences elements of the deal were covered by partner Richard Taylor, Legal Director Satnam Sahota, Senior Associate Kate Black and Associates Mary Foord-Weston and Anna Ward.